Early-stage startups don't fail from lack of effort — they fail by scaling sales and GTM before they've earned the right to ...
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results